Pharmaceutical

Catalyst Biosciences (NASDAQ:CBIO) announced operating and financial results for the fourth quarter and full-year ended December 31, 2017 and provided a corporate update. As quoted in the press release: “2017 was a pivotal year for us as we continued to make significant progress in the clinical development of both of our subcutaneously administered next-generation subcutaneously …

Catalyst Biosciences (NASDAQ:CBIO) announced operating and financial results for the fourth quarter and full-year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“2017 was a pivotal year for us as we continued to make significant progress in the clinical development of both of our subcutaneously administered next-generation subcutaneously dosed, FIX and FVIIa, coagulation factors,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “With our recent equity offering, our balance sheet provides the resources to further accelerate the clinical development programs of our Factor IX and VIIa candidates through multiple key milestones in 2018 and 2019.”

Click here to read the full press release.

MARKETS

Markets
TSX19028.86+167.50
TSXV623.23+5.97
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6612.60+72.70

COMMODITIES

Commodities
Gold1803.75-5.35
Silver19.87-0.12
Copper3.51-0.09
Palladium1933.20-4.30
Platinum880.37-3.65
Oil108.39-0.04
Heating Oil3.90-0.04
Natural Gas5.75+0.02

DOWNLOAD FREE REPORTS

×